Apollomics closes $10 million private placement, insiders take part
The Nasdaq-listed oncology company sold Class A shares to accredited investors, with its CEO, CFO, and an affiliate of its COO among the buyers.
SEC filing (2)
Latest
2 stories
Tuesday, August 18
Tuesday, July 21
Apollomics discloses full compensation and bio details for new director Yen
A follow-up SEC filing confirms Hung-Hsien Yen's board appointment and lays out his pay package and background.
SEC filing